ACTRN12605000484640已完成2 期
Randomised, double-blind, three armed, placebo controlled trial comparing the safety and efficacy of sea cucumber extract, sea cucumber extract with Boswellia extract and placebo in adults with osteoarthritis.
Faulding Healthcare Pty Ltd0 个研究点目标入组 129 人开始时间: 2005年9月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •1) Diagnosis of OA of the hip or knee. 2) Willing to discontinue all current OA treatment for the study duration commencing 4 weeks prior to baseline.
排除标准
- •1) Severe false alignment of the knee or hip2) Surgery or arthroscopy of the knee or hip within 2 months of baseline3) Infectious or inflammatory rheumatic disease4) Reliance on the use of lipolytic, fibrinolytic, anti-coagulant or anti-inflammatory agents5) A history of trauma associated with the affected joints6) Any condition that in the opinion of the investigator might interfere with the evaluation of the study objective.
研究者
相似试验
招募中
3 期
Clinical trial on eye healthCTRI/2023/12/060711BOTANIC HEALTHCARE PVT LTD
进行中（未招募）
1 期
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.Relapsing-Remitting Multiple SclerosisMedDRA version: 14.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020328-23-PTMerck Serono SA - Geneva, an affiliate of Merck KGaA,358
进行中（未招募）
不适用
A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLARRelapsing-Remitting Multiple SclerosisMedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2010-020328-23-NLMerck Serono The Netherlands - a division of Merck B.V.358
进行中（未招募）
不适用
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.EUCTR2010-020328-23-FIMerck Serono230
进行中（未招募）
不适用
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.Relapsing-Remitting Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020328-23-LTMerck Serono230